The GcMAF Book

Chapter 14

Biomarker Testing

This chapter will show you how to use AMAS testing, Nagalase testing, and viral antibody testing to determine whether you have cancer. If you do have cancer, you’ll learn how to track your treatment program to make sure it is working.

It is important to appreciate the fact that both cancers and viruses make Nagalase. Therefore, a positive Nagalase test result tells us both cancer and/or virus could be present, but it doesn’t tell us which. This problem can be easily solved. Since the AMAS test is specific for cancer (and not viral infections), a positive AMAS tells us cancer caused the Nagalase to go up. Viral antibody testing can also be used to rule specific viruses in or out. Thus the combination of AMAS and viral screening will effectively sort through the possibilities presented by a positive Nagalase test.

Here is a summary of what each test will tell you:

  • A positive Nagalase test indicates presence of either a a cancer or viral infection, or both.
  • AMAS testing (now available) indicates presence of cancer (only).
  • Viral antibody testing (now available) indicates presence of specific viruses (see list below).
  • Appropriate combinations of these three tests will sort through the possibilities and identify the actual cause of the disease.
/media/images/amasnagvirustest.png

Using Nagalase to screen for cancer

In the (hopefully not-too-distant) future, once Nagalase testing and GcMAF are available, all people at risk of cancer—i.e., everyone over the age of 40—will get an annual Nagalase test along with their other routine blood tests (complete blood count, comprehensive metabolic panel, vitamin D, lipid panel, etc.).

Nagalase will become our standard marker for early cancer detection. Those with an elevated Nagalase (after ruling out a viral cause; see below) will be treated “presumptively” (i.e., we know it’s in there even though we can’t actually see it) with GcMAF and/or other alternative cancer therapies.

Followup Nagalase testing will document the patient’s progress. Once the cancer is gone, as documented by a return of Nagalase to baseline, subsequent testing will provide an early warning if cancer starts growing again.

Using Nagalase to track effectiveness of cancer therapy

The more cancer cells present in the body, the more Nagalase they generate. Thus, Nagalase is the perfect marker for determining response to cancer therapies because, in a given patient, tumor burden will always be proportional to the Nagalase level.

In cancer patients, a declining Nagalase level reflects a reduction in total tumor “load” or “burden.” We would expect a lower Nagalase after chemo, radiation, or surgery because these treatments all reduce tumor burden. Having used these therapies does not mean the disease is gone, however. A very low (baseline) Nagalase level would indicate the cancer has been cured.

If there is even a remote chance of metastatic disease—as indicated by an elevated Nagalase level—it would be wise to use GcMAF to activate the immune system so it can find and polish off any remaining cancer cells. Repeat testing with declining levels would indicate that the treatment is working.

Using AMAS to screen for cancer

The AMAS test (Anti-Malignin Antibody in Serum) measures serum levels of AMA, an antibody found to be elevated in 99% of patients with active malignancies.

Until Nagalase is available, I recommend the AMAS as a screening test for all people over 40. See Chapter 13 for a complete description of the AMAS test.

Using AMAS to track effectiveness of cancer therapy

Tumors produce AMAS in direct proportion to their size, so declining AMAS levels indicate the cancer is shrinking and that the treatment program is working. Increasing AMAS levels, on the other hand, indicate cancer growth and that a different treatment approach should be considered. (At least three AMAS tests are required to establish a pattern.)

Using AMAS to determine whether a positive Nagalase indicates presence of cancer or virus.

Since all viruses and all cancers make Nagalase, an elevated Nagalase level could be caused by either. AMAS testing, however is specific for cancer (i.e., tells us nothing about viruses). So an elevated Nagalase and a normal AMAS indicate a viral infection. If, conversely, both Nagalase and AMAS are elevated, you know you are dealing with cancer.

Using viral antibody testing

A negative AMAS coupled with a positive Nagalase indicates the presence of a viral infection. Anti- viral antibody testing will identify the specific virus. Each virus generates its own specific antibodies. The most common chronic viral infections are listed below. Antibody testing is available for each:

  • Herpes zoster
  • Herpes Simplex I
  • Herpes Simplex II
  • Epstein-Barr virus (mononucleosis)
  • Hepatitis B
  • Hepatitis C
  • Cytomegalovirus (CMV)
  • Human Immunodeficiency Virus (HIV)

Presumptive treatment of “occult” cancer

Conventional medicine continues to prefer to wait until imaging reveals both the presence and location of a cancer before acknowledging its existence and instituting therapy. For “occult” cancers—the ones that can’t be “seen,” but testing says they’re in there somewhere—the best course of action is to treat “presumptively.” In this situation, a positive Nagalase and/or AMAS testing has told us cancer is present, so we “presume” the presence of cancer, and then go ahead and treat it even though it’s still too small to be seen on imaging. An AMAS test done twice and positive both times identifies the presence of cancer with 99% accuracy. A positive Nagalase (once this test becomes available) coupled with a positive AMAS would also constitute convincing evidence of an occult cancer.

If the treatment works, we may never actually see the cancer. This may trouble some physicians, but ask yourself this question: would you rather remove a small cancer with natural, harmless medicine, and never get to see it—or would you prefer to wait until the malignancy enlarges to the point where it’ll show up on a CAT scan, which means you’ll now need a biopsy, surgery, radiation, and chemotherapy? Hello?

Copyright © 2010 Timothy J. Smith, M.D.